Myriad Genetics to sell Prenatal Health unit to Labcorp, raises revenue guidance
The company signed a definitive deal to divest Prenatal Health to Labcorp for $210 million in cash plus inventory value, expected to close by early 2027, while nudging up full-year 2026 revenue guidance.
Myriad Genetics announced on November 4, 2026 that it reported third quarter 2026 results and raised the midpoint of its full-year revenue guidance. On October 19, 2026, the company entered into a definitive agreement to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health business at closing.1 The deal is subject to customary closing conditions, including regulatory approvals, and is expected to close by early 2027.1
Myriad said the divestiture supports a strategic shift toward its Cancer Care Continuum business, which includes screening, treatment selection, monitoring, and remission surveillance, according to CEO Sam Raha, who said the sale of the Prenatal Health business is a decisive step to support the company's strategic intent to increase profitable growth by focusing on the Cancer Care Continuum, and is expected to benefit healthcare providers, patients, employees and shareholders while improving revenue growth rate, profitability, and liquidity.1
On the pipeline side, the company said new MONSTAR-SCREEN-3 data was presented at the European Society for Medical Oncology Congress 2026 in late October, reinforcing the importance of highly sensitive molecular residual disease testing after curative-intent surgery in patients with resectable colorectal and pancreatic cancers.1 Myriad also disclosed it continues to engage the Molecular Diagnostics Program, administered by Palmetto GBA, a Medicare Administrative Contractor, seeking a Local Coverage Determination for Medicare coverage of its Precise MRD test in breast cancer.1 In October, the company announced a collaboration with SOPHiA GENETICS to advance a prostate cancer-specific genomic instability score technology with AstraZeneca.1
On guidance, Myriad raised the midpoint of its full-year 2026 revenue range to $780 million to $790 million, reflecting third quarter results and current business trends.1 As of quarter end, the company had cash and cash equivalents of $107.1 million.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.